Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients

Fig. 1

A A representative cases of breast cancer is that mesothelin (A) and CA125 (B) is diffusely positive in triple-negative breast cancer. Immunoperoxidase stain, original magnification ×400. B Relapse-free survival curves for 478 patients with breast cancer after surgery classified with the status of the expressions of mesothelin and CA125. Their co-expression group shows the worst prognosis. C-D The result of Cox’s univariate analysis is shown in forest plots, and by the Cox’s multivariate analysis, NSLN and CA125 co-expression remains as an independent prognostic factor. E Relapse-free survival curves for 333 luminal-type breast cancer patients after surgery classified with the status of the expressions of mesothelin and CA125. Their co-expression group shows the worst prognosis. F-G The result of Cox’s univariate analysis was shown in forest plots, and by the Cox’s multivariate analysis, NSLN and CA125 co-expression remains as an independent prognostic factor.

Back to article page